



Projects should be within the field of drug discovery (i.e. projects should focus on therapeutics.) Medical devices, diagnostic tools and research platforms will not be considered for the 2017 edition of the AmorChem KNOCK OUT™ Event.

Please fill in this application using point-form whenever possible. You may attach relevant publications as required (limit these to the **four most relevant**, including reviews.) The form, once completed, **should not exceed five pages** of your text at 12 pts Helvetica. **The Additional Technical Information section is not part of the five pages** and can be referred to within the form.

Explanatory notes for each section are found at the end of the form. You are encouraged to work with your commercialization or technology transfer office to answer the COMMERCIAL OPPORTUNITY section and to familiarize yourself with the AmorChem model. The percentages indicated in each section header refer to the weighting of each section in the evaluation of the projects.

The examples given in certain sections are for clarifying purposes only and should not be interpreted as indicative of our investment preferences.

THE DEADLINE FOR SUBMISSION OF THIS APPLICATION IS OCTOBER 17TH, 2017 YOU MAY SEND THE COMPLETED APPLICATION TO info@amorchem.com

CONFIDENTIALITY:

ALL APPLICATION FORMS SUBMITTED TO AMORCHEM WILL BE KEPT IN STRICT CONFIDENCE AND ONLY USED FOR THE PURPOSES OF THE AMORCHEM KNOCK OUT EVENT. AMORCHEM WILL ENTER INTO A CONFIDENTIALITY AGREEMENT WITH THE RELEVANT INSTITUTIONS IF NONE EXISTS.

NEXT STEPS:

We will announce the contenders no later than November 3rd, 2017. A conference call will be organized to explain the details of the next steps of the AmorChem KNOCK OUT Event. Contenders will need to fill out and submit a standard PowerPoint document (template to be provided by AmorChem) on or before November 17th, 2017 at 12:00 PM. Contenders will not use the presentation as support during the final round of the AmorChem KNOCK OUT Event.

It is important to keep in mind that the final presentation on December 6th, 2017 will take part in a public forum and you should contact your commercialization or technology transfer office to understand how to treat your confidential information if you are chosen as a contender.

All Contenders participating in the Event will also be required to enter into a 6-month Exclusivity Agreement with AmorChem.

PRE-INVESTMENT CONDITIONS:

The project chosen on December 6th, 2017 will have to complete the following steps to the satisfaction of AmorChem and its Investment Committee prior to receiving the AmorChem investment: 1) Intellectual Property due diligence, if pertinent; 2) Maturation Plan development and finalization; 3) Economic Terms negotiations with the originating institution; 4) Contractual negotiations with the originating institution.

CONFIDENTIAL

GENERAL

A. NAME OF LEAD INVESTIGATOR FOR THE PROPOSED PROJECT & ACADEMIC INSTITUTION	
B. AREA(S) OF CURRENT RESEARCH	
C. AREA(S) OF TRAINING	

PROPOSED PROJECT DESCRIPTION (30%)

D. TECHNOLOGY	
E. CURRENT STAGE	
F. TARGET INDICATION & PROPOSED TREATMENT MODALITY	
G. OPPORTUNITY	
H. USE OF AMORCHEM PROCEEDS	

COMMERCIAL POTENTIAL (70%)

I. MARKET OPPORTUNITY	
J. BUSINESS OPPORTUNITY	
K. EXISTING INTELLECTUAL PROPERTY	
L. POTENTIAL INTELLECTUAL PROPERTY	
M. PREVIOUS BUSINESS DEVELOPMENT EFFORTS	
N. RISKS/WEAKNESSES	

CONFIDENTIAL

ADDITIONAL TECHNICAL INFORMATION

TYPE OF TARGET (enzyme, ion channel, receptor etc)	
GENE NAME	
PATHWAY INVOLVED	
TARGET SUBSTRATE	
TISSUE DISTRIBUTION	
SUBTYPES	
KNOWN ACTIVATORS	
KNOWN INHIBITORS	
CRYSTAL STRUCTURE (yes/no)	
TARGET EXPRESSED INTRA OR EXTRA-CELLULAR	
GENETIC VALIDATION (human mutations, SNPs etc)	
KNOCK-IN OR KNOCK-OUT	
EXISTING IN VITRO ASSAYS (short list of useful assays for your Project. Please indicate which are set- up in your lab and which aren't)	
EXISTING IN VIVO ASSAYS (short list of useful assays for your Project. Please indicate which are set- up in your lab and which aren't)	
ANIMAL MODELS (short list of useful assays for your Project. Please indicate which are set- up in your lab and which aren't)	

CONFIDENTIAL

CONTACT INFORMATION FOR LEAD INVESTIGATOR

EMAIL ADDRESS	
TELEPHONE NUMBERS : <ul style="list-style-type: none">• CELL• OFFICE/LAB	
NAME OF THE CONTACT PERSON OF THE COMMERCIALIZATION OFFICE OR TECH TRANSFER OFFICE INVOLVED	

GENERAL

B. List your most current areas of research interest, including, if any, those not directly related to your proposed project. Also provide a list of your sources of funding in the past 5 years.

C. Provide a brief summary of your research background. State any area of training or specific qualification pertinent to the proposed project.

PROPOSED PROJECT DESCRIPTION (30%)

D. Describe the work on which the proposed project is based.

E. Describe the current stage of the work. Briefly describe the way in which your hypothesis is supported by existing data.

F. Name the clinical indication for a potential drug resulting from your proposed project. Indicate which treatment modality is envisaged (small molecule, biologic, delivered intra-venous, orally, sub-cutaneous etc)

G. The object of this section is to determine the competitive nature of your proposed project, and also to determine the advantage for AmorChem of working with you on this project.

As such, describe the advantages of the project, technology, intellectual property or approach from a scientific and clinical perspective. Include a short discussion of the importance and originality of your project with respect to the existing treatment paradigm.

List any specific attributes of your results, insight or research tools that will confer an advantage to your lab when executing the project funded by AmorChem. For example: is there population genetic validation for the use of your target? Have you completed some knock-out work to validate its use? Have you already set up a specific suite of assays which will be required in the execution of the project? Etc.

CONFIDENTIAL

H. Describe the 2-year project you are proposing to accomplish with a \$500,000 AmorChem investment. Describe the overarching goal of the proposed project and the main deliverable that will emanate from its successful execution.

List the steps and intermediate deliverables leading to this goal. Indicate which steps would be considered decision-making points for pursuing the project. For the purposes of this application form, the project described does not have to be in final, detailed form: a summary will suffice.

If possible, indicate which tools exist in your lab to do the proposed project and which have to be developed. If applicable, indicate the work that needs to be done in third party labs, including contract research organizations such as NuChem Therapeutics Inc. (for medicinal chemistry.)

COMMERCIAL POTENTIAL (70%)

I. Briefly describe the market targeted by your project. Be as specific as possible in the identification of the subgroup of patients that would benefit from the potential drug.

Compare your potential drug product to those already on the market or in development. Describe how your project will yield a product that is differentiated from the competition. Include, if relevant, any potential benefit brought by the predicted treatment modality.

J. The purpose of this section is to determine how you believe your project can attract commercial interest. As such, describe how the main deliverable (s) stemming from your project will fulfill an unmet medical need, from a commercial perspective.

K. Indicate whether your technology has been the object of patents or patent applications, and if so, please indicate the date of filing (s). Interaction with your institution's commercialization or technology transfer office to fill out this section is recommended. Please note that AmorChem does not require for patents to be already filed in order to contemplate an investment.

L. Describe what Intellectual Property might result from the proposed project. Interaction with your institution's commercialization or technology transfer office to fill out this section is recommended.

M. Indicate whether approaches have been made in the past to pharmaceutical or biotechnology companies to commercialize your technology by yourself or by the appropriate commercialization or technology transfer office.

N. List the risks associated with your project, both from a technical perspective (near-term "execution" risk) and from a commercial perspective (longer-term business risk for a potential acquirer.) These should include any barriers to entry you can identify.